A meta-analysis shows that the relative benefit of BP-lowering is evident when baseline SBP is ≥140mmHg, but not if it is <140 mmHg, particularly in primary prevention.
AHA 2017 Prof. Clyde Yancy summarizes the most important new recommendations, starting with a new definition of hypertension, the need for a risk conversation and implications for therapy.
AHA 2017 In the SPRINT study, BP was not always measured in absence of a physician or nurse. A posthoc survey investigated whether this affected the findings of the study.
AHA 2017Although the broad statements remain intact, the target in BP lowering differs between Europe and USA; prof Yancy explains why.
AHA 2017 The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods.
AHA 2017 A lot of variation in BP measurement methods was seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.
AHA 2017 Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.
AHA 2017 Gastric bypass in obese hypertensives (BMI 30-39.9) led to stable BP and reduction of medication need in the majority of patients, and about half showed remission after 1 year.
Although midlife hypertension is more common in men, it was only associated with the risk of dementia in women, suggesting that hypertension is a modifiable risk factor for dementia in women.
In a double-blind, randomized study, treatment with sacubitril/valsartan in hypertensive patients reduced the LV mass index to a greater extent than olmesartan.
ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.
In a SPRINT-eligible ACCORD-BP population, a high-risk cohort of diabetic patients, intensive BP control at a goal of <120 mmHg, reduced CVD outcomes.